Amyotrophic Lateral Sclerosis clinical trials

The registry lists 979 studies for Amyotrophic Lateral Sclerosis across more than 10 countries. 278 are recruiting or about to start. 856 of them are mainly about Amyotrophic Lateral Sclerosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 1,020 studies for Amyotrophic Lateral Sclerosis. How that becomes 977 here

This page counts the studies the registry files under Amyotrophic Lateral Sclerosis, and those it files under no condition that list Amyotrophic Lateral Sclerosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

1,020Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−6List Amyotrophic Lateral Sclerosis as a condition, but the registry did not file them under itMost often written as “Sporadic Amyotrophic Lateral Sclerosis” (3), “Amyotrophic Lateral Sclerosis 11” (1), and “Amyotrophic Lateral Sclerosis And/or Frontotemporal Dementia” (1). The registry filed them under other conditions only, most often Amyotrophic lateral sclerosis 1 (3) and Amyotrophic Lateral Sclerosis 11 (1).
−37Match it another way29 name it in the title and 8 by a synonym or other text the search reads.
977The count on this page2 of them list Amyotrophic Lateral Sclerosis in their own words; the registry filed them under no condition.

Get an email when these change. Save the Amyotrophic Lateral Sclerosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 436
Recruiting: 193
Status unknown: 90
Terminated: 70
Not yet recruiting: 65
Active, not recruiting: 53

Phase

Phase 2: 274
Phase 1: 172
Phase 3: 91
Early Phase 1: 20
Phase 4: 8

Where

United States: 440
France: 132
Italy: 89
Canada: 82
Germany: 76
United Kingdom: 69

Who runs them

Assistance Publique - Hôpitaux de Paris (21) · Peking University Third Hospital (21) · Massachusetts General Hospital (20) · Johns Hopkins University (12) · National Institute of Neurological Disorders and Stroke (NINDS) (11) · University of Michigan (11) · Mayo Clinic (10) · Drexel University College of Medicine (10)

What is being tested here

Drugs under test in Amyotrophic Lateral Sclerosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
LY4256984	3	0	3
nL-CHCHD-001	2	0	4
Masitinib	2	3	3
Psilocybin	2	0	2
Memantine	1	2	5
Tofersen	1	1	3
Pridopidine	1	3	3
SPG-302	1	1	3
Debamestrocel	1	2	3
Riluzole	1	0	3

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Serotonin receptor agonists 3 open · Bronchodilators 1 open · Antimitotic agents 1 open · Integrase inhibitors 4

Coming up

20phase 3 studies under way

102studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Apr 2027Study of COYA 302 for the Treatment of ALS · Phase 3 · Coya Therapeutics
Apr 2027Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS · Phase 3 · MediciNova
Apr 2027Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS · Phase 3 · Mario Negri Institute for Pharmacological Research
Jun 2027This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling · Phase 3 · Gipfel Life Sciences GmbH
Jul 2027HEALEY ALS Platform Trial - Master Protocol · Phase 3 · Merit E. Cudkowicz, MD
Jul 2027HEALEY ALS Platform Trial - Regimen I NUZ-001 · Phase 3 · Merit E. Cudkowicz, MD
Jul 2027RAPA-501 Therapy for ALS · Phase 3 · Rapa Therapeutics LLC
Aug 2027Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms · Phase 3 · Biogen
Sep 2027A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) · Phase 3 · Shanghai Zhimeng Biopharma, Inc.
Nov 2026High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project · Istituti Clinici Scientifici Maugeri SpA

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger. 15 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 55 (28%) take healthy volunteers.

Recruiting studies that take each age, of 193
Age	Women	Men
10	13 (7%)	13 (7%)
18	176 (91%)	176 (91%)
30	191 (99%)	191 (99%)
40	192 (99%)	192 (99%)
50	193 (100%)	193 (100%)
65	192 (99%)	192 (99%)
75	181 (94%)	181 (94%)
85	143 (74%)	143 (74%)

Across all 979 studies, recruiting or not: 20% stop at 75 or younger and 6% at 65; 8% take children; <1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Amyotrophic Lateral Sclerosis studies take

Of 73 phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	21 mo13–41 · 70 studies	21 mo9–38 · 40 studies	19 mo16–41 · 30 studies
Phase 1/2	33 mo25–57 · 36 studies	—	—
Phase 2	24 mo16–35 · 73 studies	21 mo15–35 · 36 studies	32 mo18–41 · 37 studies
Phase 2/3	25 mo18–109 · 22 studies	—	—
Phase 3	28 mo25–60 · 24 studies	—	—
Interventional, no phase	35 mo23–60 · 154 studies	—	40 mo24–60 · 134 studies
Observational	64 mo29–114 · 137 studies	—	67 mo30–125 · 128 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Show 3 more

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).Oct 20, 2026NCT07883590
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Oct 15, 2026NCT07875972
Brain-Computer Interface Communication Device for People With ALSOct 13, 2026NCT07871071

Studies

Recruiting first, then most recently updated. Showing 50 of 979. Browse all 979 → or search them.